CTOs on the Move

Epic Sciences

www.epicsciences.com

 
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic`s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient`s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic`s goal ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Jason Christiansen
Chief Technology Officer Profile
Chockalingam Palaniappan
Chief Technology Officer Profile
Dave Henderson
Chief Information Officer Profile
Dave Henderson
Chief Information Officer Profile
Michael Giske
Chief Information Officer Profile

Funding

Epic Sciences raised $15M on 06/01/2015
Epic Sciences raised $40M on 04/28/2017
Epic Sciences raised $43M on 06/01/2022

Similar Companies

Enthrive

Enthrive is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Limelight Bio

Limelight is a privately held, multi-platform, multi-disease biopharmaceutical company headquartered in Philadelphia, PA and Cambridge, MA

Zosano Pharma Inc

Zosano Pharma Inc is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CytomX

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.

Viracta

Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.